Movatterモバイル変換

[0]ホーム

Jump to content

Minretumomab

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Minretumomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	TAG-72
Clinical data
Other names	CC49
ATC code	V09IX03 (WHO) (¹²⁵I radiolabelled)
Identifiers
CAS Number	195189-17-4^N
ChemSpider	none
UNII	235435CH6L
^NY (what is this?) (verify)

Minretumomab (CC49) is amouse monoclonal antibody^[1] that was designed for the treatment ofcancers that express theTAG-72 antigen. This includesbreast,colon,lung, andpancreatic cancers.^[2]^[3] Apparently, it never got pastPhase I clinical trials for this purpose.^[4]

Derivatives

[edit]

A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric^[5] and humanized minretumomab,^[6] as well as afusion protein of a minretumomabsingle-chain variable fragment and the enzymebeta-lactamase.^[7]

Radiopharmaceuticals

[edit]

Iodine (¹²⁵I) minretumomab is aniodine-125 radiolabelled derivative that was developed for the detection oftumours inradioimmunoassays such asCA 72-4.^[8]

Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (¹³¹I) and lutetium (¹⁷⁷Lu) minretumomab, for example, were shown to inducehuman anti-mouse antibodies; no tumour response was observed in Phase I and IIclinical trials.^[5]

References

[edit]

^"International Nonproprietary Names for Pharmaceutical Substances (INN)"(PDF).WHO Drug Information.13 (3). 1999.
^"TAG-72 antigen".NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.
^Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer".Nature Reviews. Cancer.12 (4):278–87.doi:10.1038/nrc3236.PMID 22437872.S2CID 205469234.
^"Studies found for: CC49".ClinicalTrials.gov.
^^a ^bTrahan Rieger P, ed. (2001).Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335.ISBN 0-7637-1428-3.
^Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW (February 2010)."Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72".Cancer.116 (4 Suppl):1059–66.doi:10.1002/cncr.24793.PMC 4498458.PMID 20127951.
^Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, et al. (2006). "Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)".Bioconjugate Chemistry.17 (2):410–8.doi:10.1021/bc0503521.PMID 16536473.
^Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, et al. (November 1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay".Cancer Research.56 (22):5293–8.PMID 8912871.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab (+hyaluronidase) Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Retrieved from "https://en.wikipedia.org/w/index.php?title=Minretumomab&oldid=1241509000"

Category:

Monoclonal antibodies for tumors

Hidden categories:

[8]ページ先頭